EGFR-TKIs are administered to patients with NSCLC who had EGFR-activating mutations, and careful attention should be paid to patients with COPD, pneumonitis, pneumonia, and inflammatory cytokine-enriched circumstances when selecting EGFR-TKI treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.